Lake Street analyst Thomas Flaten maintained a Buy rating on DermTech (DMTK – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $3.13.
Flaten covers the Healthcare sector, focusing on stocks such as Assertio Therapeutics, Castle Biosciences, and Achieve Life Sciences. According to TipRanks, Flaten has an average return of -1.5% and a 32.58% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for DermTech with a $6.00 average price target.
See the top stocks recommended by analysts >>
DMTK market cap is currently $97.31M and has a P/E ratio of -0.80.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DMTK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company is headquartered in La Jolla, CA.
Read More on DMTK:
